This article is more than 5 years old. Information may no longer be current.
Cardiology Today's Intervention top 5 articles posted in September
Cardiology Today ’s Intervention compiled a list of the top 5 stories posted to Healio.com/Intervention in September.
This month, Cardiology Today’s Intervention readers were most interested in the benefits of PFO closure on reduced risk for recurrent stroke, conscious sedation vs. general anesthesia in TAVR, percutaneous closure vs. surgical cutdown, the results of the ILLUMENATE EU trial, PCI vs. CABG in left main CAD treatment and much more.
Three new studies show benefit of PFO closure on reduced risk for recurrent stroke
New data from the CLOSE, REDUCE and RESPECT trials demonstrated a lower rate of recurrent ischemic stroke after patent foramen ovale closure compared with antiplatelet therapy alone in patients with a PFO and recent cryptogenic stroke.
The new data are in contrast to three other recent trials published in the past 5 years — CLOSURE I, PC and RESPECT (2013) — that did not show the same benefit of PFO closure over medical therapy in this patient population.
Conscious sedation linked to lower mortality vs. general anesthesia in TAVR
Transcatheter aortic valve replacement with conscious sedation was linked to shorter length of stay and lower in-hospital and 30-day mortality vs. TAVR with general anesthesia in adjusted and unadjusted analyses, according to new data published in Circulation.
“Many changes to the devices have facilitated more minimally invasive processes of care,” Jay Giri, MD, MPH, from the division of cardiovascular medicine at the hospital of the University of Pennsylvania and Penn Cardiovascular Quality, Outcomes and Evaluative Research Center and a Cardiology Today Next Gen Innovator, told Cardiology Today’s Intervention. “The natural next step for us to investigate is: What about the need for general anesthesia? Should TAVR more closely resemble an open surgical aortic valve replacement or should it more closely resemble a PCI?”
Percutaneous system for access-site closure beneficial vs. surgical cutdown
LAS VEGAS — Percutaneous closure of large-bore arterial access sites was associated with positive outcomes compared with surgical cutdown, according to data presented at VIVA 17.
The percutaneous closure device (Perclose ProGlide, Abbott Vascular) was associated with fewer blood transfusions and infections, lower mortality and shorter length of stay compared with surgical cutdown, Darren Schneider, MD, associate professor and chief of vascular and endovascular surgery at the NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, said here.
ILLUMENATE: DCB yields durable treatment effect at 2 years
LAS VEGAS — New data from the ILLUMENATE EU randomized controlled trial demonstrate higher primary patency and a lower rate of clinically driven target lesion revascularization at 2 years after treatment with a drug-coated balloon, compared with percutaneous transluminal angioplasty.
Researchers for the trial randomly assigned 294 patients with symptomatic femoropopliteal disease on a 3:1 basis to receive the DCB (Stellarex, Spectranetics/Philips) or PTA. The DCB was approved by the FDA in July.
PCI comparable to CABG in left main CAD treatment
Although CABG has been the standard therapy for patients with left main coronary artery stenosis, new data suggest that PCI with drug-eluting stents may be a valid alternative treatment.
Daniele Giacoppo, MD, from the German Heart Center Munich and the Technical University of Munich, and colleagues performed a meta-analysis recently published in JAMA Cardiology comparing long-term safety of PCI with DES vs. CABG in patients with left main coronary artery stenosis.